Navigation Links
New study shows that a cough medicine ingredient could effectively treat prostate cancer
Date:12/18/2008

Baltimore, MD -- A study published today in the December issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer. Researchers found that noscapine, which has been used in cough medication for nearly 50 years, reduced tumor growth in mice by 60% and limited the spread of tumors by 65% without causing harmful side effects.

Prostate cancer is the most common cancer among men in the United States. The American Cancer Society estimates that 186,320 men will be diagnosed with prostate cancer in 2008 and 28,660 will die from it. One man in 6 will get prostate cancer during his lifetime. Although slow-growing in most men, the cancer is considered advanced when it spreads beyond the prostate. There is no known cure.

The laboratory study was a joint effort by Dr. Israel Barken of the Prostate Cancer Research and Educational Foundation, Moshe Rogosnitzky of MedInsight Research Institute, and Dr. Jack Geller of The University of California San Diego. Noscapine has previously been studied as a treatment for breast, ovarian, colon, lung and brain cancer and for various lymphomas, chronic lymphocytic leukemia and melanoma. This study, however, is the first to demonstrate its effectiveness in treating prostate cancer.

Noscapine is a naturally-occurring substance, a non-addictive derivative of opium. As a natural substance, noscapine cannot be patented, which has limited the potential for clinical trials. Rogosnitzky notes that drug companies are generally unwilling to underwrite expensive clinical trials without being able to recoup their investment. A synthetic derivative of noscapine has been patented but has not yet reached the clinical testing phase.

Since noscapine is approved for use in many countries as a cough suppressant, however, it is available to doctors to prescribe for other uses as well. This common practice is known as "off-label" prescription. Noscapine is increasingly being used off-label to treat a variety of cancers. Dr. Barken used noscapine to treat a handful of prostate cancer patients before retiring from clinical practice. Encouraged by the success of these treatments, his foundation funded the laboratory study being reported in the December 2008 edition of Anticancer Research.

As founder and medical director of the Prostate Cancer Research and Educational Foundation in San Diego, Dr. Barken is encouraging academic institutions to follow up this successful laboratory research with a human clinical trial. He has pioneered a web-based patient tracking system that will greatly reduce the cost of the trial while cutting the time necessary to complete the study. Using the web-based tracking system will also allow doctors outside the U.S. to enroll patients in the research.

Rogosnitzky, director of research at MedInsight Research Institute, points out the significant advantages that noscapine could present as a treatment for prostate cancer. "Noscapine is effective without the unpleasant side effects associated with other common prostate cancer treatments. Because noscapine has been used as a cough-suppressant for nearly half a century, it already has an extensive safety record. This pre-clinical study shows that the dose used to effectively treat prostate cancer in the animal model was also safe."

Hormone therapy and chemotherapy, along with radiation and surgery, are currently used to slow the progression of advanced prostate cancer. Side effects resulting from these treatments include impotence, incontinence, fatigue, anemia, brittle bones, hair loss, reduced appetite, nausea and diarrhea. No toxic side effects were observed in the laboratory study of noscapine.


'/>"/>

Contact: Dr. Israel Barken
drbarken@pcref.org
619-461-8181
MedInsight Research Institute
Source:Eurekalert

Related medicine news :

1. Common treatment for mens pelvic pain proves ineffective, Queens-led study shows
2. Study indicates how we make proper movements
3. Study Finds Molecular Link Between Obesity, Hypertension
4. Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
5. Annals colonoscopy study underscores importance of quality standards
6. Study: Sandwich Generation Struggling With Dual Caregiver Responsibilities
7. Recent UC Davis Study Finds Strawberries May Reduce Risk of Heart Disease
8. UIC receives $16 million to study impact of environment on kids health
9. Study examines how breastfeeding impacts cost of care for very low birth weight infants
10. Abused women seek more infant health care, MU study finds
11. New Easter Seals-MassMutual Study: Autism Strains Family Finances, Threatens Long-Term Care and Security
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... AWARE: A Week of Addiction and Recovery Education, from April 24 to April ... preventing substance use disorders. , The mission of AWARE is to instill ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... announced an exciting new partnership with the highly regarded and well renowned Asian ... highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and ...
(Date:4/21/2017)... Worcestershire, UK (PRWEB) , ... April 21, 2017 ... ... Award for Enterprise in the category of International Trade, the UK’s most prestigious ... in international trade, which represents 95% of total revenues and has grown by ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology: